Cholesterol, VLDL - Drug effects
Research News and Information

Sunday, November 22, 2009

Safety and efficacy of achieving very low low-density lipoprotein cholesterol levels with rosuvastatin 40 mg daily (from the ASTEROID Study).

2 May 2009 Clinical trial evidence supports the use of intensive statin therapy for patients with coronary artery disease. High doses of potent statins have shown the greatest clinical benefit, but concerns persist regarding the efficacy and safety of ... Read more...

Effect of garlic (Allium sativum) on heavy metal (nickel II and chromium VI) induced alteration of serum lipid profile in male albino rats.

30 Aug 2008 We have studied the effect of simultaneous oral treatment of aqueous garlic extract (Allium sativum) on heavy metal (nickel II and chromium VI) induced changes in serum lipid profile. Nickel sulfate and potassium dichromate treated rats showed a ... Read more...

Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia.

20 May 2008 Prescription omega-3 acid ethyl esters (P-OM3) are commonly used for treatment of very high triglyceride levels, often in combination with a statin, to lower persistent hypertriglyceridemia. This randomized, crossover trial evaluated 6 weeks of ... Read more...

Latest indexed articles for 'Cholesterol, VLDL - Drug effects'

These are the very latest articles for this heading:

• Safety and efficacy of achieving very low low-density lipoprotein cholesterol levels with rosuvastatin 40 mg daily (from the ASTEROID Study). 2 May 2009
• Effect of garlic (Allium sativum) on heavy metal (nickel II and chromium VI) induced alteration of serum lipid profile in male albino rats. 30 Aug 2008
• Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia. 20 May 2008
• Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. 28 Feb 2008
• Hypolipidemic activity of Indan--1--acetic acids. 27 Feb 2006
• LPL-mediated lipolysis of VLDL induces an upregulation of AU-rich mRNAs and an activation of HuR in endothelial cells. 19 Feb 2006
• Coronary calcification in body builders using anabolic steroids. 30 Dec 2005
• Long-term treatment of N-3 PUFAS on plasma lipoprotein levels and fatty acid composition of total serum and erythrocyte lipids in hypertriglyceridemic patients. 30 Jan 2005
• Short-term effect of bezafibrate on the expression of adiponectin mRNA in the adipose tissues: a study in spontaneously type 2 diabetic rats with visceral obesity. 29 Nov 2004
• Treatment of hypertriglyceridemia with omega-3 fatty acids: a systematic review. 30 Aug 2004
• Phenolics-rich extracts from Silybum marianum and Prunella vulgaris reduce a high-sucrose diet induced oxidative stress in hereditary hypertriglyceridemic rats. 30 Jul 2004
• Impaired intravascular triglyceride lipolysis constitutes a marker of clinical outcome in patients with stable angina undergoing secondary prevention treatment: a long-term follow-up study. 14 Jun 2004
• The recycling of apolipoprotein E and its amino-terminal 22 kDa fragment: evidence for multiple redundant pathways. 14 May 2004
• Fish protein improves blood pressure but alters HDL2 and HDL3 composition and tissue lipoprotein lipase activities in spontaneously hypertensive rats. 8 Mar 2004
• The efficacy and safety of the new heparin-induced extracorporeal low-density lipoprotein precipitation system (Plasmat Futura) in comparison with the currently used system (Plasmat Secura). 30 Jan 2004
• Influence of hydrogenated fat and butter on CVD risk factors: remnant-like particles, glucose and insulin, blood pressure and C-reactive protein. 30 Oct 2003
• Effect of tamoxifen on fibrinogen, D-dimer, lipid and lipoprotein concentrations in breast cancer patients. 30 Oct 2003
• The potential beneficial effect of leptin on an experimental model of hyperlipidemia, induced by chronic ethanol treatment. 30 Oct 2003
• Effects of lifestyle modification and lipid intake variations on patients with peripheral vascular disease. 29 Sep 2003
• Serum cholesterol efflux potential is an independent predictor of coronary artery atherosclerosis. 30 Aug 2003

See a longer list of these articles.

Technical information about 'Cholesterol, VLDL'

Definition: Cholesterol which is contained in or bound to very low density lipoproteins (VLDL). High circulating levels of VLDL cholesterol are found in HYPERLIPOPROTEINEMIA TYPE IIB. The cholesterol on the VLDL is eventually delivered by LOW-DENSITY LIPOPROTEINS to the tissues after the catabolism of VLDL to INTERMEDIATE-DENSITY LIPOPROTEINS, then to LDL.

Registry Number: 0

Descriptor UI: D015243

Alternative terms: Cholesterol, VLDL; Prebetalipoprotein Cholesterol; Cholesterol, Prebetalipoprotein; VLDL Cholesterol; Pre-beta-Lipoprotein Cholesterol; Cholesterol, Pre-beta-Lipoprotein; Pre beta Lipoprotein Cholesterol; Very Low Density Lipoprotein Cholesterol;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; drug effects; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; ultrastructure; urine; chemistry; contraindications; agonists;

Tree Number: D10.532.599.700; D10.570.938.208.285; D12.776.521.622.700;

History Note: 2007 (1989)